



Ifw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Alan R. Fritzberg
Title: SKELETAL-TARGETED RADIATION TO TREAT BONE-ASSOCIATED PATHOLOGIES
Docket No.: 295.054US1
Filed: June 20, 2003
Examiner: Unknown
Serial No.: 10/601,081
Due Date: N/A
Group Art Unit: 1616

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

We are transmitting herewith the following attached items (as indicated with an "X"):

- ☒ A return postcard.
- ☒ A Communication Concerning Related Applications (1 pg.).
- ☒ A Supplemental Information Disclosure Statement (1 pg.), Form 1449 (1 pg.), and copies of 4 cited documents.

If not provided for in a separate paper filed herewith, Please consider this a **PETITION FOR EXTENSION OF TIME** for sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
Customer Number 21186

By: Warren D. Woessner
Atty: Warren D. Woessner
Reg. No. 30,440

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 14th day of February, 2005.

Dawn M. Poole
Name

Dawn M. Poole
Signature

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
(GENERAL)



N 10/601,081

PATENTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Alan R. Fritzberg	Examiner:	Unknown
Serial No.:	10/601,081	Group Art Unit:	1616
Filed:	June 20, 2003	Docket:	295.054US1
Title:	SKELETAL-TARGETED RADIATION TO TREAT BONE-ASSOCIATED PATHOLOGIES		

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to MPEP 609, Applicant requests that a copy of the Form 1449, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

Pursuant to 37 C.F.R. § 1.97(b), it is believed that no fee or statement is required with the Supplemental Information Disclosure Statement. However, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Supplemental Information Disclosure Statement considered. The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,
ALAN R. FRITZBERG
By his Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6903


Date 2-14-05

By W. D. Woessner
Warren D. Woessner
Reg. No. 30,440

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. on this 14th day of February, 2005.

Dawn M. Poole
Name

Dawn M. Poole
Signature



S/N 10/601,081

PATENTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Alan R. Fritzberg Examiner: Unknown
Serial No.: 10/601,081 Group Art Unit: 1616
Filed: June 20, 2003 Docket: 295.054US1
Title: SKELETAL-TARGETED RADIATION TO TREAT BONE-ASSOCIATED
PATHOLOGIES

COMMUNICATION CONCERNING RELATED APPLICATIONS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicant would like to bring to the Examiner's attention the following related applications in the above-identified patent application.

<u>Serial/Patent No.</u>	<u>Filing Date</u>	<u>Attorney Docket</u>	<u>Title</u>
10/615484	July 8, 2003	295.034US1	THERAPEUTIC AND DIAGNOSTIC COMPOUNDS, COMPOSITIONS, AND METHODS
10/014335 6,767,531	December 11, 2001	295.044US1	HIGH DOSE RADIONUCLIDE COMPLEXES FOR BONE MARROW SUPPRESSION
10/159245	May 29, 2002	295.044US2	HIGH DOSE RADIONUCLIDE COMPLEXES FOR BONE MARROW SUPPRESSION
10/172363	June 14, 2002	295.052US1	SKELETAL TARGETED RADIATION TO TREAT BONE-ASSOCIATED PATHOLOGIES
10/784476	February 23, 2004	295.044US3	HIGH DOSE RADIONUCLIDE COMPLEXES FOR BONE MARROW SUPPRESSION
10/882054	June 30, 2004	295.044US4	HIGH DOSE RADIONUCLIDE COMPLEXES FOR BONE MARROW SUPPRESSION
11/041828	January 24, 2005	295.044US5	HIGH DOSE RADIONUCLIDE COMPLEXES FOR BONE MARROW SUPPRESSION

Respectfully submitted,
ALAN R. FRITZBERG
By Applicant's Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6903

Date 2-14-05By Warren D. Woessner

Warren D. Woessner
Reg. No. 30,440

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 14th day of February, 2005.


Name

Signature

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)



Complete if Known

Application Number	10/601,081
Filing Date	June 20, 2003
First Named Inventor	Fritzberg, Alan
Group Art Unit	1616
Examiner Name	Unknown

Sheet 1 of 1

Attorney Docket No: 295.054US1

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
--------------------	---------------------	------------------	---	----------------------------

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T ²
--------------------	---------------------	------------------	---	----------------

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		"Abstract Book, Annual Congress of the EANM", <u>European Journal of Nuclear Medicine and Molecular Imaging</u> , 31, Helsinki, 2004, including abstracts P908, P925-P936, and P946-P952 (2004).	
		"Manufacture of Triethylene Tetramine", <u>Research Disclosure</u> , 315, Number 31591, 595 (1990).	
		GOLDMAN, "Good Drug, Bad Luck: Business, Regulatory Issues Can Create Obstacles for Drug Development", <u>Journal of the National Cancer Institute</u> , 96, 1573-1574 (2004).	
		KYLE et al., "Multiple Myeloma", <u>The New England Journal of Medicine</u> , 351, 1860-1873 (2004).	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached